Cannabis

From connections between cannabis use and schizophrenia to some non-psychiatric medications that may worsen symptoms of major depression, here are highlights from the week in Psychiatric Times.

A look at the association between cannabis use and schizophrenia, as well as the need for comprehensive public health policies and education.

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

What is the association between cannabis use disorders and schizophrenia? Researchers used a nationwide register-based cohort study to investigate these associations.

Explore the complex interaction of cannabis and psychosis, and the sociocultural stressors and resulting neurobehavioral symptoms.

Should cannabis be regulated in the United States in a manner similar to alcohol and tobacco?

"It is essential to have an aggressive path forward to increase public awareness of mental health and illness, education on early intervention and treatment access, and continued destigmatization of mental illness."

Catch up on the latest CMEs in Psychiatric Times.

From special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community, here are highlights from the week in Psychiatric Times.

The agency’s conclusions are based on regulatory oversight needed to manage risks associated with CBD and other cannabis-derived products.

Remember to keep the cart behind the horse while practicing medicine.

Revisiting the CME articles featured in Psychiatric Times in 2022.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

While there are no FDA-approved medications available for CUD, some studies show potential off-label utility in mitigating withdrawal and maintaining abstinence. Learn more in this CME article.

Herbal medicines have been used to treat mental health disorders since ancient times, and continue to be useful today.

What is the effect of cannabis use on adherence to medications in patients with psychosis?

Cannabis use disorder and nonadherence: How can we best educate patients?

In honor of National CBD Day, Psychiatric Times™ shares some recent expert discussions on the pros, cons, and clinical implications of cannabis use in psychiatry.

What's the latest update on cannabis legislation and its clinical utility?

Is cannabis’ effect on schizophrenia being downplayed?

10 keys to understanding the science of cannabinoids.

Research on psychiatrists' attitudes on the potential of cannabis in psychiatry.

Enlightening survey results reveal what psychiatrists think about medical marijuana/cannabis use, how or whether to discuss with their patients, and what biases might get in the way of such conversations.

The sharply decreasing perception of risk and easy accessibility of cannabis has many patients turning towards it, despite the potential negative effects.

Cannabis use has prompted symptoms such as dizziness, sleepiness, and fatigue in older patients. Are there any benevolent effects?

The rapidly changing field of cannabinoids and their clinical implications poses a particular challenge in psychiatry.

A synthesis of quantitative reviews on the relationship between cannabis use and psychosis.

What are your thought about navigating these uncharted waters?

What are your thoughts about prescribing medical marijuana/cannabis to treat psychiatric disorders?

What are your feelings about the utility of cannabis in psychiatric practice?